THE EFFICIENCY, SAFETY, AND TOLERANCE OF ROSUVASTATIN THERAPY IN VERY HIGH CARDIOVASCULAR RISK PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA: PRELIMINARY RESULTS OF THE 40x40 STUDY


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

The main objective of the pilot 40 x 40 study was to evaluate the hypolipidemic efficacy, safety, and tolerance of the generic rosuvastatin Mertenil in a high daily dose of 40 mg/day in very high cardiovascular risk patients who failed to achieve low-density lipoprotein cholesterol goals during current statin therapy in daily clinical practice. The data of a follow-up during the first 12-week therapy are given.

全文:

受限制的访问

作者简介

M. Zubareva

Russian Cardiology Research-and-Production Complex, Ministry of Health and Social Development of Russia

Email: asus99@mail.ru
Candidate of Medical Sciences

T. Rozhkova

Russian Cardiology Research-and-Production Complex, Ministry of Health and Social Development of Russia

Email: asus99@mail.ru
Candidate of Medical Sciences

N. Gornyakova

Russian Cardiology Research-and-Production Complex, Ministry of Health and Social Development of Russia

Email: asus99@mail.ru
Candidate of Medical Sciences

E. Solovyeva

Russian Cardiology Research-and-Production Complex, Ministry of Health and Social Development of Russia

Email: asus99@mail.ru
Candidate of Medical Sciences

A. Susekov

Russian Cardiology Research-and-Production Complex, Ministry of Health and Social Development of Russia

Email: asus99@mail.ru
MD

V. Kukharchuk

Russian Cardiology Research-and-Production Complex, Ministry of Health and Social Development of Russia

Email: asus99@mail.ru
MD, Correspondent Member of the Russian Academy of Medical Sciences Laboratory of Clinical Lipidology, Department of Atherosclerosis Problems

参考

  1. ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) // Eur. Heart J. - 2011; 32 (14): 1769-818.
  2. Cholesterol Treatment Trialist’s CTT Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins // Lancet. - 2005; 366: 1267-78.
  3. CTT Collaborators. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials // Lancet. - 2010; 376: 1670-81.
  4. CTT Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials // Lancet. - 2012; 380 (9841): 581-90.
  5. Law M., Wald N., Rudnicka A. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis // BMJ. - 2003; 326 (7404): 1423.
  6. Jones P., Davidson M., Stein E. et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial) // Am. J. Cardiol. - 2003; 92 (2): 152-60.
  7. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. 5-й пересм. - М., 2012.
  8. Оганов Р.Г., Кухарчук В.В., Арутюнов Г.П. и др. Сохраняющиеся нарушения липидного спектра у пациентов с дислипидемиями, получающих статины в реальной клинической практике в Российской Федерации (российская часть исследования DYSIS) // Кардиоваск. тер. и профилакт. - 2012; 4: 1-10.
  9. Константинов В.О. Новое в профилактике атеросклероза и его осложнений // Справ. поликлинич. врача. - 2012; 2: 7-12.
  10. Stalenhoef A., Ballantyne C., Sarti C. et al. A COmparative study with rosuvastatin in subjects with METabolic Syndrome: results of the COMETS study // Eur. Heart J. - 2005; 26: 2664-72.
  11. Strandberg T., Feely J., Sigurdsson E. DISCOVERY study group. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study // Clin. Ther. - 2004; 26 (11): 1821-33.
  12. Sorof J., Berne Ch., Siewert-Delle A. et al. Effect of rosuvastatin or atorvastatin on urinary albumin excretion and renal function in type 2 diabetic patients // Diab. Res. Clin. Practice. - 2006; 72: 81-7.
  13. Schuster H., Barter P., Stender S. et al. Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study // Am. Heart J. - 2004; 147: 705-12.
  14. Ballantyne C., Raichlen J., Cain V. Statin Therapy Alters the RelationshipBetween Apolipoprotein B and Low-Density Lipoprotein Cholesterol. and Non-High-Density Lipoprotein Cholesterol. Targets in High-Risk PatientsThe MERCURY II (Measuring EffectiveReductions in Cholesterol Using Rosuvastatin therapY II) // Trial. J. Am. Coll. Cardiol. - 2008; 52: 626-32.
  15. Betteridge D., Gibson J., Sager Ph. Comparison of Effectiveness of Rosuvastatin Versus Atorvastatin on the Achievement of Combined C-Reactive Protein (<2 mg/L) and Low-Density Lipoprotein Cholesterol (<70 mg/dl) Targets in Patients With Type 2 Diabetes Mellitus (from the ANDROMEDA Study) // Am. J. Cardiol. - 2007; 100: 1245-8.
  16. Pitt B., Loscalzo J., Monyak J. et al. Comparison of Lipid-Modifying Efficacy of Rosuvastatin Versus Atorvastatin in Patients With Acute Coronary Syndrome (from the LUNAR Study) // Am. J. Cardiol. 2012; 109: 1239-46.
  17. Задионченко В.С., Шахрай Н.Б., Шехян Г.Г. и др. Особенности фармакологических и клинических свойств розувастатина // Рус. мед. журн. - 2011; 12: 772-8.
  18. Задионченко В.С., Шехян Г.Г., Шахрай Н.Б. и др. Влияние розувастатина на липидный обмен, микроциркуляцию и показатели центральной гемодинамики у больных с острым коронарным синдромом // Consilium Medicum. -2011; 5: 85-9.
  19. Гиляревский С.Р., Орлов В.А., Кузьмина И.М. и др. Гиполипидемические эффекты интенсивных режимов применения статинов при лечении больных с острым коронарным синдромом: подходы к выбору препарата и его дозы // Кардиол. и сердечно-сосуд. хир. - 2012; 5 (4): 36-41.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Russkiy Vrach Publishing House, 2012
##common.cookie##